Investors

2017 News

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
11/09/17Forward Pharma to Participate in the Nordic-American Life Science Conference
COPENHAGEN, Denmark, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Nordic-American Life Science Conference being held November 13-14, 2017 in New York, NY. Dr. Svendsen will speak on the CXO Panel on Monday, November 13, 2017 at 9:00 AM ET and host one-on-one meetings. About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company tha... 
Printer Friendly Version
09/26/17Forward Pharma Reports Financial and Operational Results from the First Six Months of 2017
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the six-month period ended June 30, 2017.  Net income for the six-month period ended June 30, 2017 was $941.2 million, or $1.91 per diluted share, versus net loss of $(32.0) million, or $(0.07) per share for the six-month period ended June 30, 2016.  “We are pleased to announce our results for the first half year of 2017, where majo... 
Printer Friendly Version
09/05/17Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) of the opening brief for the appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent. “We continue to believe that our intellectual property is strong and that ... 
Printer Friendly Version
09/01/17Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders
COPENHAGEN, Denmark, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the final approval by the Company’s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”). On September 1, 2017, following this approval, the Company effected the Capital Reduction with a distribution of proceeds to holders of ordinary shares. The record date for holders... 
Printer Friendly Version
08/02/17Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting
COPENHAGEN, Denmark, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the result of the extraordinary general meeting of its shareholders held on August 2, 2017 (the “Extraordinary General Meeting”), where the requisite majority of the votes cast approved the plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”). Forward has received... 
Printer Friendly Version
07/18/17Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders
COPENHAGEN, Denmark, July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction. This decision is based on a careful evaluation of the most appropriate capital allocation strategy after receipt of the non-refundable USD 1.25 billion cash fee from Biogen. The capital reduction aligns the amount of working capital with t... 
Printer Friendly Version
06/14/17Forward Pharma CEO to Present at the JMP Securities 2017 Life Sciences Conference on June 20, 2017
COPENHAGEN, Denmark, June 14, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the JMP Securities 2017 Life Sciences Conference being held June 20-21, 2017 in New York, NY. Dr. Svendsen will present on Tuesday, June 20, at 3:30 PM ET and host one-on-one meetings before and after the presentation. Investors and other interested parties may access a live audio webcast of ou... 
Printer Friendly Version
06/02/17Forward Pharma CEO to Present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017
COPENHAGEN, Denmark, June 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference being held June 6-9, 2017 in New York, NY. Dr. Svendsen will present on Tuesday, June 6, at 3:00 PM ET and host one-on-one meetings before and after the presentation. Investors and other interested parties may access a live audio webcast of our ... 
Printer Friendly Version
05/31/17Forward Pharma Appeals the Initial Decision in the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark, May 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of the notice of appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent. The appeal was filed to the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”) and seeks to have the decision overturned and the interference reinstated.... 
Printer Friendly Version
05/01/17Forward Pharma CEO to Present at the 42nd Annual Deutsche Bank Health Care Conference on May 4, 2017
COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference, being held May 3-4, 2017 in Boston, MA. Dr. Svendsen will present on Thursday, May 4, at 10:40 AM ET and host one-on-one meetings before and after the presentation. Investors and other interested parties may access a live audio webcast of our... 
Printer Friendly Version
05/01/17Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement
COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”) today provided an update on the Company’s strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and License Agreement with Biogen. Consistent with the focus on executing on the intellectual property strategy and the planned timeline for conclusion of ongoing research and development activities, Executive Vice Presidents R... 
Printer Friendly Version
04/18/17Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results
COPENHAGEN, Denmark, April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016. Net income for the fourth quarter December 31, 2016 was $9.6 million while net loss for the year ended December 31, 2016 was $33.3 million, or $0.20 and $(0.71) per diluted share, respectively. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our... 
Printer Friendly Version
03/31/17Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
COPENHAGEN, Denmark, March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that it intends to file an appeal challenging today’s decision by the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) in Pat... 
Printer Friendly Version
03/01/17Forward Pharma Appoints Claus Bo Svendsen as Chief Executive Officer and Plans to Reorganize to Reduce Burn Rate Following the Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen, M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017. He previously held the position of Executive Vice President at the Company. Dr. Svendsen succeeds Peder M. Andersen, M.D., who has led the Company since 2012. Dr. Andersen will retain his role as Chief Operating Officer and serve until Septe... 
Printer Friendly Version
02/09/17Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned subsidiaries of Biogen Inc. and certain other parties (the “License Agreement”). On January 17, 2017 Forward entered into the License Agreement subject to the approval of its shareholders and certain... 
Printer Friendly Version
02/01/17Forward Pharma Announces Results of Extraordinary General Meeting
Forward obtains shareholder approval for Settlement and License Agreement with Biogen COPENHAGEN, Denmark, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that, at an extraordinary general meeting of its shareholders held on February 1, 2017 (the “Extraordinary General Meeting”), the requisite two-thirds majority of the votes cast as well as the share capital represented at the Extraordinary General Meeting approved the entry into a Settle... 
Printer Friendly Version
01/17/17Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory approvals COPENHAGEN, Denmark, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has entered into a binding agreement with two wholly owne... 
Printer Friendly Version